Krensavage Asset Management LLC Has $11.12 Million Position in BioNTech SE (NASDAQ:BNTX)

Krensavage Asset Management LLC lowered its stake in BioNTech SE (NASDAQ:BNTX - Free Report) by 29.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 93,583 shares of the company's stock after selling 38,710 shares during the quarter. BioNTech comprises approximately 6.2% of Krensavage Asset Management LLC's holdings, making the stock its 7th largest holding. Krensavage Asset Management LLC's holdings in BioNTech were worth $11,115,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in BNTX. FMR LLC grew its holdings in shares of BioNTech by 797.8% in the third quarter. FMR LLC now owns 6,299,929 shares of the company's stock valued at $748,243,000 after purchasing an additional 5,598,190 shares in the last quarter. Fred Alger Management LLC bought a new position in BioNTech during the third quarter valued at $59,485,000. Candriam S.C.A. grew its stake in shares of BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock worth $46,526,000 after buying an additional 418,695 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in shares of BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company's stock worth $37,103,000 after buying an additional 341,311 shares during the last quarter. Finally, Braidwell LP purchased a new stake in shares of BioNTech during the 3rd quarter valued at about $29,425,000. Institutional investors own 15.52% of the company's stock.

BioNTech Trading Up 2.4 %

BioNTech stock traded up $2.88 during trading hours on Friday, hitting $121.72. The company had a trading volume of 992,408 shares, compared to its average volume of 1,076,621. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The firm has a market cap of $29.18 billion, a P/E ratio of -57.96 and a beta of 0.22. The company has a 50-day moving average price of $113.91 and a two-hundred day moving average price of $99.62. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. During the same quarter in the previous year, the firm posted $0.73 earnings per share. The company's revenue was up 38.9% on a year-over-year basis. On average, sell-side analysts anticipate that BioNTech SE will post -3.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BNTX has been the subject of several recent research reports. BMO Capital Markets reiterated an "outperform" rating on shares of BioNTech in a research report on Monday, December 2nd. Jefferies Financial Group upgraded BioNTech from a "hold" rating to a "buy" rating and lifted their target price for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. TD Cowen cut their target price on BioNTech from $132.00 to $122.00 and set a "hold" rating on the stock in a research report on Tuesday, November 5th. Evercore ISI upgraded BioNTech from an "in-line" rating to an "outperform" rating and raised their price target for the stock from $110.00 to $125.00 in a research report on Tuesday, November 19th. Finally, The Goldman Sachs Group raised shares of BioNTech from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $90.00 to $137.00 in a research note on Friday, November 8th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, BioNTech currently has a consensus rating of "Moderate Buy" and a consensus price target of $138.67.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.